drug response phenotype
Evidence from:
primary |
all sources
No related entities found.
Mentioned in (14)
Papers in which this entity is mentioned.
- Flexynesis: A deep learning toolkit for bulk multi-omics data integration for precision oncology and beyond. (2025)
- Genome-wide association testing beyond SNPs. (2025)
- Synthetic augmentation of cancer cell line multi-omic datasets using unsupervised deep learning. (2024)
- The landscape of drug sensitivity and resistance in sarcoma. (2024)
- Analysis of 10,478 cancer genomes identifies candidate driver genes and opportunities for precision oncology. (2024)
- The Application of Long-Read Sequencing to Cancer. (2024)
- RNA splicing dysregulation and the hallmarks of cancer. (2023)
- Widespread Selection for Oncogenic Mutant Allele Imbalance in Cancer. (2018)
- Patient-derived xenografts undergo mouse-specific tumor evolution. (2017)
- Mutational landscape of metastatic cancer revealed from prospective clinical sequencing of 10,000 patients. (2017)
- Development and clinical application of an integrative genomic approach to personalized cancer therapy. (2016)
- A gene-based association method for mapping traits using reference transcriptome data. (2015)
- HLAreporter: a tool for HLA typing from next generation sequencing data. (2015)
- Reflections on the cost of "low-cost" whole genome sequencing: framing the health policy debate. (2013)
Merged raw entities (2)
All extracted name/type variants the normalize job merged into this entity. Use this to spot wrong merges, or aliases that should be split off.
| Raw name | Type | Papers | Mentions |
|---|---|---|---|
| drug response | phenotype | 17 | 26 |
| inter‑individual differences in drug response | phenotype | — | — |